Leo A. Kim, M.D., Ph.D.



Diabetic Retinopathy

Macular Degeneration

Board Certification

  • Ophthalmology

Main Campus
243 Charles Street
Boston, MA 02114
Phone: 617-391-5896
Stoneham-Retina Consultants
1 Montvale Avenue
Stoneham, MA 02180
Phone: 781-662-5520



Dr. Leo Kim is a retina surgeon and a full time member of the Retina Service who has extensive experience in the management of retinal diseases associated with neovascularization or angiogenesis. These include diseases such as retinal vein occlusions, diabetic retinopathy, and age-related macular degeneration. He sees patients at two locations-at Mass. Eye and Ear's main campus on Charles Street and at the Mass. Eye and Ear Retina Consultants office at 1 Montvale Ave. in Stoneham.

After obtaining his MD/PhD from the Medical Scientist Training Program at Yale University School of Medicine, Dr. Kim attended University of Southern California/Doheny Eye Institute for his ophthalmology residency, where he was recognized with the Doheny Resident Research Award for two consecutive years. He also was awarded the Lillian and Henry Nesburn Award for Research Excellence and was chosen to participate in the 2008 Heed Ophthalmic Foundation Residents Retreat-;an honor extended to only the top residents in the United States demonstrating exceptional potential in academic ophthalmology. Following residency, Dr. Kim continued at Doheny Eye Institute as a vitreoretinal surgery fellow and was recognized by the Heed Foundation with a highly prestigious fellowship grant.

As a clinician scientist and a member of the K12 Harvard Vision Clinical Scientist Development Program, which is funded by the National Institutes of Health/National Eye Institute, Dr. Kim focuses his research on understanding the mechanisms of vitreoretinal disease. He is particularly interested in the mechanisms of retinal toxicity associated with the use of systemic medications such as tamoxifen. In addition, he performs research on the molecular mechanisms of proliferative diabetic retinopathy, evaluating the cell biology of fibrovascular membranes and the genetics of PDR. He also performs translational research on the prognosis of non-exudative age-related macular degeneration.

In addition to providing clinical and surgical supervision to residents and fellows, Dr. Kim also supervises and trains laboratory members. He teaches during the annual, national Mass. Eye and Ear Vitrectomy Course and has presented on topics such as retinal surgery and tamoxifen toxicity both nationally and internationally.

Clinical Interests

Retinal diseases associated with neovascularization or angiogenesis, including diabetic retinopathy, and age-related macular degeneration

Research Interests

Cell biology and genetics of diabetic retinopathy; orbital lymphaniogenesis in thyroid eye disease; retinal toxicities; oxygen models of age-related macular degeneration


For a full list of publications, please see his CV.

A brief history of anti-VEGF for the treatment of ocular angiogenesis. Kim LA, D'Amore PA. The American Journal of Pathology. 2012;181(2):376-9.

Clinical characteristics of a large choroideremia pedigree carrying a novel CHM mutation. Huang AS, Kim LA, Fawzi AA. Archives of Ophthalmology. 2012;130(9):1184-9.

Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Sohn EH, He S, Kim LA, Salehi-Had H, Javaheri M, Spee C, Dustin L, Hinton DR, Eliott D. Archives of Ophthalmology. 2012;130(9):1127-34.

Vascular endothelial growth factor is important for brown adipose tissue development and maintenance. Bagchi M, Kim LA, Boucher J, Walshe TE, Kahn CR, D'Amore PA. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2013;27:3257-71.

The role of genetics in the pathogenesis of periocular cutaneous neoplasms: implications for targeted therapy. Lee NG, Kim LA, Freitag SK. Seminars in Ophthalmology. 2013;28(5-6):267-74.

Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Kim LA, Amarnani D, Gnanaguru G, Tseng WA, Vavvas DG, D'Amore PA. Invest Ophthalmol Vis Sci. 2014 Jul 3;55(8):4747-58.

Ocriplasmin for treatment of stage 2 macular holes: early clinical results. Miller JB, Kim LA, Wu DM, Vavvas DG, Eliott D, Husain D. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul-Aug;45(4):293-7.

Retinal microangiopathy in a mouse model of inducible mural cell loss. Valdez CN, Arboleda-Velasquez JF, Amarnani DS, Kim LA, D'Amore PA. Am J Pathol. 2014 Oct;184(10):2618-26.

View a list of publications on pubmed.gov>>

To learn more about Dr. Kim, read his "Meet a Specialists profile" here.



  • Biomedical Engineering, Johns Hopkins University, BS
  • Yale University School of Medicine, Ph.D.
  • Yale University School of Medicine, M.D.


  • Ophthalmology, USC Doheny Eye Institute


  • Retina and Vitreous Surgery, USC Doheny Eye Institute